BioRestorative Therapies Inc Dossier
Qualitative Analysis
Business overview
BioRestorative Therapies, Inc. (NASDAQ: BRTX) is a clinical-stage regenerative medicine company focused on developing therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. The company's primary clinical program is the Disc/Spine Program, featuring its lead candidate BRTX-100, an autologous cultured mesenchymal stem cell therapy formulated from a patient's own bone marrow. BRTX-100 is designed for the non-surgical treatment of chronic lumbar disc disease (cLDD) and has been granted FDA Fast Track designation. Additionally, the company is developing its ThermoStem metabolic program, which utilizes brown adipose-derived stem cells to target obesity and metabolic disorders. BioRestorative also operates a commercial BioCosmeceutical platform to generate near-term revenue streams.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Accelerating the commercial strategy and market reach of the company's proprietary cell-based secretome and exosome-enriched biologic skincare portfolio.
Expected impact: Aims to establish a high-growth, recurring commercial revenue stream in the regenerative aesthetics and advanced skincare markets.
Continued development and global patent expansion of the ThermoStem platform, a cell-based brown adipose tissue therapy targeting obesity and metabolic disorders.
Expected impact: Positions the company to offer a potentially longer-lasting and safer cell-based alternative to the multi-billion dollar GLP-1 drug market.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Dr. Goldberg, a global dermatology leader, will lead the clinical evaluation of the company's regenerative BioCosmeceutical platform to drive professional and physician-channel adoption.
Terms: Not publicly disclosed
Collaborating to build, brand, and commercialize the company's BioCosmeceutical platform.
Terms: Not publicly disclosed